Development, Characterization and in vivo evaluation of Tovaptan solid dispersions via solvent evaporation technique by K, Ramesh et al.
   
 
International Journal of Drug Delivery 7 (2015) 32-43 
http://www.arjournals.org/index.php/ijdd/index 
 
Original Research Article 
             
Development, characterization and in vivo evaluation of Tolvaptan solid 
dispersions via solvent evaporation technique   
Ramesh K*1, Chandra Shekar  B2, Khadgapathi  P3, Bhikshapathi D.V.R.N4, Renuka K4 
 
*Corresponding author: 
 
Ramesh  K 
 
1JNTUH, Kukatpally, Hyderabad - 
500072, Telangana, India. 
2Bomma Institute of Pharmacy, 
Allipuram, Khammam - 507318, 
Telangana, India. 
3Hetero Labs Ltd, Hyderabad - 500055, 
Telangana, India. 
4Vijaya College of Pharmacy, Hayath 
Nagar, Hyderabad - 501511, 
Telangana, India. 
 
 
 
 
 
 
 
 
 
A b s t r a c t  
Investigation on in vitro and in vivo behavior of solid dispersions containing Tolvaptan is the focus of 
the present research work. The effect of various hydrophilic polymers on the aqueous solubility was 
studied. Kleptose HPB was selected as carrier and solid dispersions were prepared by solvent 
evaporation technique. Evaluation of solid dispersion for percentage yield, drug content and 
solubility was most appropriate. Solid dispersions of drug: Kleptose HPB: SLS (1:2:1 ratio) (SE8) 
shown higher dissolution rate i.e. 96.8 % compared with and pure drug (39.6%) and other 
formulations.  Differential scanning calorimetry and powder X-ray diffraction performed on solid 
dispersion showed that Tolvaptan existed in the amorphous form within the solid dispersion 
formulation fabricated using the solvent evaporation process. Additionally, scanning electron 
microscopy studies suggested the conversion of crystalline Tolvaptan to an amorphous form. In vivo 
studies of pure drug and optimized formulation (SE8) were carried out in male Wistar rats and 
pharmacokinetic parameters   calculated using Kinetica software 2000.  In vivo studies revealed that 
a marked increase in dissolution and bioavailability was exhibited by optimized Tolvaptan solid 
dispersion (SE8).  AUC (0-t) was increased more than 2.11 folds, Cmax increased about 2.67 folds 
and tmax reduced by 1 hour, when compared to the pure drug. Thus, the study has illustrated the 
potential use of a solid dispersion system for the delivery of a very poorly soluble drug tolvaptan with 
a better bioavailability. Therefore, the solid dispersions prepared by solvent evaporation method 
using Kleptose HPB as hydrophilic carrier can be successfully used for improvement of dissolution 
of Tolvaptan and resulted in faster onset of action as indicated by in vivo studies. 
Keywords: Tolvaptan, hydrophilic carriers, solvent evaporation technique, solubility, solid 
dispersions. 
Introduction 
More than 40 percent of the drug coming from high throughput 
screening are poorly water soluble in water with poor permeability  
are increasingly posing challenges in the development of new 
drugs, since a large number of drugs coming directly from 
synthesis or from high throughput screening have a very poor 
solubility. It is well known that drug efficacy can be severely limited 
by poor aqueous solubility, leading to low dissolution rate and thus 
results in low absorption in the gastrointestinal tract after oral 
administration hence comprising oral bio-availability. The ability to 
increase aqueous solubility is thus a valuable aid to increase the 
efficacy for certain drugs [1]. 
One of the major challenges of pharmaceutical formulation 
scientists is to develop the oral dosage forms of poor aqueous 
solubility drugs, hence, two areas of pharmaceutical research that 
focus on improving the oral bioavailability of active agents include 
enhancing solubility and dissolution rate of poorly water-soluble 
drugs and enhancing permeability of poorly permeable drugs [2]. 
Solubility is one of the important physic-chemical property to be 
considered for formulation development and it is a predetermined 
and rate limiting step for drug absorption. There are many methods 
like salt formation, solubilisation and particle size reduction to 
enhance oral bioavailability of poorly soluble drugs. However, 
techniques such as size reduction increases dissolution and 
bioavailability but, micronization often leads to aggregation and 
agglomeration, which leads to poor wettability of particles [3].  
This problem is rectified by preparation of solid dispersion of poorly 
water soluble drugs by using water soluble carriers. Poorly soluble 
drugs when formulated as tablet or capsule dosage forms it 
disintegrate into large solid particles in GI tact, which leads to poor 
dissolution and less absorbed into the body system. Significantly, 
solid dispersion disintegrates into colloidal particle of particle size 
less than 5 microns which enhances the dissolution rate of the 
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drug. Among all the methods, solid dispersion has been widely 
used to increase oral bioavailability, solubility and dissolution rate 
of the drug [4]. 
Tolvaptan is relatively a new chemical and pharmacologic class of 
drug known as aquaretic sorvaptans [5]. 
Tolvaptan (INN) is a selective, competitive vasopressin receptor 2 
antagonist used to treat hyponatremia (low blood sodium levels) 
associated with congestive heart failure, cirrhosis, and the 
syndrome of inappropriate antidiuretic hormone (SIADH). 
Tolvaptan was developed by Otsuka Pharmaceutical Co. and 
approved by the U.S. Food and Drug Administration in 2009. It is 
the first and acquire V2-receptor antagonist in Chinese market [6]. 
 Tolvaptan vasopressin antagonist role by increasing the excretion 
of urine sleep, enhance free water clearance, reduced urine 
osmolality, and increased serum sodium values, while not 
changing the urine and serum potassium, sodium and potassium 
secretion content. Tolvaptan is mainly metabolized by CYP3A4 [7].  
Materials and Methods 
Materials 
SAMSCA® (Tolvaptan) 30 mg conventional tablets were obtained 
from Otsuka Pharmaceutical Ltd, Germany. Tolvaptan was gifted 
by Hetero drugs limited, Hyderabad, India. Kolliphor P 407 and 
Kolliphor P188 were obtained from BASF, US. Kolliwax GMS II, 
Kolliphor RH-40, Kolliphor EL, Kolliphor HS-15, Kolliphor TPGS, 
Kollidon 30, Kollidon CL, Soluplus and Kollidon® VA 64 was 
procured from BASF, Germany. Kleptose®  HPB was gifted from 
Roquette  Pharma, France. HPMC AS, MG Grade and Methocel 
HPMC 2.5cPs was were gifted by Dow Chemicals, USA. All other 
chemicals used were of analytical grade. 
Methods  
Preliminary solubility studies of Tolvaptan  
Solubility measurements of Tolvaptan were performed according to 
a published method [8]. An excess amount of Tolvaptan was added 
to 25ml of aqueous solution of water soluble carriers like Kolliphor 
RH-40, Kolliphor EL, Kolliphor TPGS, Kolliphor HS-15, Kolliphor P 
188, Kolliphor P 407, Kolliwax GMS II, Soluplus, DSS 100%, 
Kleptose HPB, HPMC AS, Kollidon 30, HPMC 2.5 cPs and mixture 
of Kolliphor P407& P188 in 1:1 and then drug to polymer to SLS in 
1:1:1 were taken in screw capped bottles. Samples were shaken 
for the 48 hours at room temperature. Subsequently, the 
suspensions were filtered through a Whatman filter paper no 1. 
Filtered solutions were analyzed for the Tolvaptan in UV/Visible 
spectrophotometer at 269 nm.  
Preparation of solid dispersions of Tolvaptan by solvent 
evaporation method 
Tolvaptan solid dispersions of fourteen formulations were prepared 
by using various carriers Summarized in Table 1 (i.e. Kolliphor 
P407, Kolliwax GMS - II, Kleptose HPB, HPMC AS, Soluplus, 
Kolliphor P188 etc.,) with SLS in proportions viz. 1:1:1, 1:2:1 (Drug: 
Carrier: Surfactant). The drug and carrier along with SLS was 
dissolved in Methanol and triturated in dry mortar until the solvent 
is evaporated and a clear film of drug and carrier was obtained. 
Then the dispersion was subjected to Methanol solvent 
evaporation by placing in 50ĈC chamber for 30 min period. The 
resultant solid dispersion was scraped out with a spatula. Solid 
dispersions were pulverized in a mortar and pestle and passed 
through a 420 μm (ASTM #40 mesh) mesh before packing in an 
airtight container [9]. 
Table 1: Formulation plan of Tolvaptan solid dispersions  
S. 
No 
 
Ingredients 
SE
1 
SE
2 
SE
3 
SE
4 
SE
5 
SE
6 
SE
7 
SE
8 
SE 
9 
SE 
10 
SE 
11 
SE
12 
SE
13 
SE
14 
1:1 1:2 1:1 1:2 1:1 1:2 1:1 1:2 1:1 1:2 1:1 1:2 1:1 1:2
1. Tolvaptan (gm) 1 1 1 1 1 1 1 1 1 1 1 1 1 1
2. HPMC AS, (MG Grade) (gm) 1 2 - - - - - -  - - - - -
3. Kolliwax GMS II (gm) - - 1 2 - - - - - - - - - -
4. Kolliphor P407 (gm) - - - - 1 2 - - - - - - - -
5. Kleptose HPB (gm) - - - - - - 1 2 - - - - - -
6. Kolliphor P188 - - - - - - - - 1 2 - - - -
7. Mixture of Kolliphor P407& P188 in 1:1(gm) - - - - - - - - - - 1 2 - -
8. Soluplus (gm) - - - - - - - - - - - - 1 2
9. SLS (gm) 1 1 1 1 1 1 1 1 1 1 1 1 1 1
10. Methanol (mL) Qs Qs Qs Qs Qs Qs Qs Qs Qs Qs Qs Qs Qs Qs
 
Solubility studies of Tolvaptan solid dispersion by 
solvent evaporation method 
A solubility measurement of Tolvaptan was performed according to 
a published method [10]. Solid dispersion samples were shaken for 
the 48 hours at room temperature. Subsequently, the suspensions 
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were filtered through a Whatman filter paper no 1. Filtered 
solutions were analyzed for the tolvaptan by UV/Visible 
spectrophotometer at 269 nm.  
Evaluation of Tolvaptan solid dispersions 
Solid dispersions obtained from the above methods were tested for 
the % Practical yield, drug content and in-vitro release studies.  
% Practical Yield 
% of practical yield was calculated to know about percent yield or 
efficiency of any method, thus its help in selection of appropriate 
method of production. SDs were collected and weighed to 
determine practical yield (PY) from the following equation.  
                      
Practical weight (Solid dispersion) 
% Practical Yield =    ----------------------------------------------    X 100 
                             Theoretical weight (Drug + Polymer + Surfactant) 
Drug content  
Accurately weighed quantity of Tolvaptan solid dispersion which is 
equivalent to 30mg of Tolvaptan was taken in volumetric flask and 
the volume is made to 100ml with methanol. From this 1ml of 
solution is taken in a 10ml volumetric flask and is made up to 10ml 
with methanol. This solution is diluted to 10øg/ml and absorbance 
was measured at λmax 269 nm against blank. The actual drug 
content was calculated using the following equation as follows: 
 
                              Actual amount of drug in solid dispersion 
% Drug content = ------------------------------------------------      X 100 
                            Theoretical amount of drug in solid dispersion 
In vitro release studies 
The dissolution test was performed using USP type 2 (paddle type) 
dissolution apparatus (Electro lab) with 900 ml of 0.22% Sodium 
Lauryl Sulfate in water as a dissolution medium at an temperature 
of   37μ0.50C with a paddle speed of 50 rpm. The solid dispersion 
equivalent to 30 mg of Tolvaptan was added and the sample of 
10ml were withdrawn at 5, 10, 15, 30, 45 and 60 minutes time 
intervals and replaced with the same volume of the dissolution 
medium. The obtained samples were analyzed for cumulative 
percentage release by using UV-Visible spectrophotometer at 
269nm.  
Fourier Transform Infrared Spectroscopy (FTIR) 
FTIR spectra for pure drug, physical mixture and optimized 
formulations were recorded using a Fourier transform Infrared 
spectrophotometer. The analysis was carried out in Shimadzu-IR 
Affinity 1 Spectrophotometer. The IR spectrum of the samples was 
prepared using KBr (spectroscopic grade) disks by means of 
hydraulic pellet press at pressure of seven to ten tons [11].  
Differential Scanning Calorimetry (DSC) 
Differential Scanning Calorimetry (DSC) studies were carried out 
using DSC 60, having TA60 software, Shimadzu, Japan. 
Accurately weighed samples were placed on aluminium plate, 
sealed with aluminium lids and heated at a constant rate of 
5ÀC/min, over a temperature range of 0 to 250ÀC [12]. 
Powder X-ray diffraction 
A Bruker D8 diffractometer was used to perform powder X-ray 
diffraction (PXRD) of all samples. A Cu K-đ 1 tube was the source, 
set at 40 KV and 50mA. A scan from 2 to 600 2 θ was carried out at 
a rate of 0.012200 2θ/s. The diffractometer was calibrated using 
powdered đ-alumina. Hot-melt extruded samples were ground 
before analysis [13]. 
Scanning electron microscopy  
The shape and surface morphology of the Tolvaptan and optimized 
formulation of solid dispersion prepared by solvent evaporation 
was examined using XL 30 model JEOL 6800 scanning electron 
microscope (Japan) [14]. 
Stability studies 
Prepared solid dispersions were placed inside sealed 40cc HDPE 
container with child resistant cap and charged at an accelerated 
stability conditions of 40 μ20C / 75 μ5% RH. Samples were 
unloaded after 1, 2, 4 and 6 months, evaluated for % drug content 
and in vitro dissolution study and compared with those SD tested 
immediately after preparation [15].  
In vivo bioavailability studies  
Male Wister rats (weighing approximately 250μ25 g) were procured 
from institutional animal house. The study protocol was approved 
by the Institutional Animal Ethics Committee (IAEC NO: 
P28/VCP/IAEC/2014/3/DBP/AE12). Twelve healthy Wister rats 
were used for this study weighing 250μ25 g. Rats were divided in 
to two groups at random each group containing six animals. First 
group was administered Tolvaptan (as such) suspension was 
prepared in 0.5% w/w HPMC 2.5cPs, second group was 
administered optimized preparation of solid dispersion suspension 
(Formulation SE8) was prepared in 0.5% w/w HPMC 2.5cPs by 
oral route at an equivalent dose of 30 mg/kg body weight. About 
500 øl of blood was withdrawn from retro orbital plexus at different 
time intervals such as 0.25, 0.50, 1.00, 1.50, 2.00, 2.50, 3.00, 4.00, 
5.00, 6.00, 8.00, 12.00 and 24.00h. Blood samples were 
transferred into eppendorf tubes containing heparin in order to 
prevent blood clotting. The samples were centrifuged immediately 
at 4000 rpm and the plasma was stored in light-protected container 
at -20 0C till analysis. The concentration of Tolvaptan from plasma 
was measured by using reversed phase HPLC. The 
chromatographic system consisted of RP-C18 chromatographic 
column, Phenomenex Kinetex (150 mm ï 4.6 mm i.d) and a mobile 
phase consisting of Water: Acetonitrile (40:60) as eluent at flow 
rate 1.0 ml / min. UV detection was at 254nm. Retention times of 
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Tolvaptan and internal standard Metronidazole was 4.50 and 
5.45min respectively. 
Pharmacokinetic analysis   
The pharmacokinetic parameters employed to evaluate were 
maximum plasma concentration (Cmax), time to attain Cmax i.e., 
Tmax and t ó values, area under plasma concentrationătime curve 
from zero to the last sampling time (AUC0-t), area under plasma 
concentrationătime curve from zero to infinity (AUC0-¥) and mean 
residence time (MRT). AUC0-t was calculated by the linear 
trapezoidal rule and AUC0-¥ from the following formula. 
AUC0-¥ = AUC0-t + Ct / KE 
Results and Discussion  
Preliminary solubility studies of Tolvaptan  
In case of solid dispersions initially preliminary solubility analysis 
were carried out to select the suitable water soluble carriers for the 
preparation of solid dispersion in which pure drug solubility was 
found to be 0.04 mg/ml (Table 2).  
From the solubility results physical mixtures Shown in Table 2 of 
drug substance and Kleptose HPB with SLS in the ratio of 1:1:1 
shown the highest drug solubility i.e. 0.11 mg/ml almost 3 fold 
increased as compared to that of pure drug. For all the water 
soluble / hydrophilic carriers used in preliminary solubility studies, 
except Kolliphor P407, Kleptose, Kolliwax, HPMC 2.5 cPs, mixture 
of Kolliphor P407 and P188 in 1:1 ratio, Kolliphor P188 and 
Soluplus, gave turbid solutions. The results are tabulated in Table 
2, and graphical representation was is shown in Figure 1. 
 
Table 2:  Preliminary Solubility studies of tolvaptan in different polymers with SLS 
S. No Sample (Physical mixtures) Drug :Polymer: Surfactant ratios Solubility(mg/ml)*
1. Pure drug - 0.04μ0.02
2. Drug: Kolliphor RH-40:SLS 1:1:1 0.09μ0.01
3. Drug: Kolliphor EL:SLS 1:1:1 0.08μ0.02
4. Drug: Kolliphor TPGS:SLS 1:1:1 0.08μ0.02
5. Drug: Kolliphor HS-15:SLS 1:1:1 0.09μ0.01
6. Drug : Kolliphor P188:SLS 1:1:1 0.10μ0.03
7. Drug : Kolliphor P 407:SLS 1:1:1 0.10μ0.04
8. Drug : Kolliwax GMS II:SLS 1:1:1 0.09μ0.01
9 Drug : Soluplus:SLS 1:1:1 0.10μ0.01
10. Drug : DSS 100%:SLS 1:1:1 0.08μ0.03
11. Drug : Kleptose HPB:SLS 1:1:1 0.12μ0.04
12. Drug : HPMC AS:SLS 1:1:1  0.10μ0.02
13. Drug: Kollidon 30:SLS 1:1:1 0.09μ0.03
14. Drug: Poloxamers (mixture of Kolliphor P407 and P188 in 1:1 :SLS 1:1:1 0.10μ0.03
*MeanμSD, range, n=3 
 
 
 
Figure 1: Solubility studies of Tolvaptan physical mixture
0
0.02
0.04
0.06
0.08
0.1
0.12
0.14
0.16
0.18
Physical mixure of drug with carriers
So
lu
bi
lty
 in
 m
g/
m
l
Ramesh et al.  International Journal of Drug Delivery 7 (1) 32-43 [2015] 
 
 
  
PAGE | 36 |
 
Preparation of Tolvaptan solid dispersions 
Solid dispersions of Tolvaptan were prepared by using Kolliphor 
P407, Kleptose,   Kolliwax GMS II, HPMC 2.5 cPs, mixture of 
Kolliphor P 407 and P188 in 1:1 ratio, Kolliphor P188 and Soluplus 
in 1:1 and 1:2 with equal proportion of SLS (to that of drug 
substance). In the present investigation 14 formulations were 
prepared and their complete composition is shown in Table 3.  All 
the solid dispersions prepared were found to be fine and free           
flowing powders. Solid dispersions SE8 is shown in Figure 2. 
 
 
Figure 2: Formulation SE 8 
Evaluation parameters 
Solubility studies of Tolvaptan solid dispersions 
Fourteen formulations of solid dispersions were prepared by 
solvent evaporation method with their respective carriers. After 
preparation of solid dispersion solubility analysis was carried out, 
this is compared with pure drug. The formulation with Kleptose 
HPB and SLS in the ratio of 1:2:1 (drug to carrier to surfactant) 
which had increased the solubility by 8 fold as compared to that of 
the pure drug (Pure drug solubility is 0.04 mg / ml and Drug with 
carriers in SE8 is 0.33 mg/ml,). The results are tabulated in Table 
3. 
Table 3: Solubility studies for solid dispersions 
 
S. No. Formulation Solubility (mg/ml)*
1 Pure drug 0.04μ0.02 
2 SE1 0.22μ0.01
3 SE2 0.24μ0.01
4 SE3 0.20μ0.03
5 SE4 0.23μ0.02
6 SE5 0.24μ0.01
7 SE6 0.25μ0.03
8 SE7 0.30μ0.01
9 SE8 0.33μ0.02
10 SE9 0.24μ0.04
11 SE10 0.26μ0.02
12 SE11 0.23μ0.01
13 SE12 0.25μ0.02
14 SE13 0.24μ0.01
15 SE14 0.27μ0.03
*Range n=3 
 
 
Figure 3: Solubility studies of Tolvaptan solid dispersions  
 
Practical yield and Drug content 
The results of % practical yield for all formulations of solid 
dispersions found to be 86.48% - 97.01%. Maximum yield was 
found to be 97.01% in formulation SE8. The drug content of the 
prepared solid dispersions was found to be in the range of 84.56 - 
97.90%. Maximum % drug content i.e. 97.90% was founds in the 
formulation SE8. The results of % practical yield and drug content 
are shown in Table 4. 
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Table 4: % practical yield and drug content for different formulations of Tolvaptan Solid dispersions  
S. No  Formulations % Yield* Drug content (%)** 
1 SE1 95.12μ4.15 95.19μ2.70 
2 SE2 96.15μ3.90 96.24μ2.45 
3 SE3 88.15μ4.50 85.62μ2.20 
4 SE4 89.54μ3.45 87.52μ3.30 
5 SE5 86.48μ5.06 84.56μ1.25 
6 SE6 87.42μ2.70 85.45μ3.20 
7 SE7      96.7μ4.40 97.48μ1.40 
8 SE8      97.01μ3.35 97.90μ1.20 
9 SE9 93.25μ4.18 92.56μ3.85 
10 SE10 92.02μ5.24 91.45μ2.84 
11 SE11 92.27μ4.74 87.62μ2.24 
12 SE12 91.16μ3.08 88.52μ2.12 
13 SE13 94.14μ2.92 96.03μ3.45 
14 SE14 96.15μ1.94 97.80μ4.10 
                       * MeanμSD, n=20                 **MeanμSD, n=3 
 
In vitro dissolution studies 
The drug release data obtained for formulations SE1-SE14 are 
tabulated in Table 5 and 6. The Table shows the cumulative 
percent drug released as a function of time for all formulations. 
Cumulative percent drug released after 90 min was 91.1%, 93.6%, 
76.8%, 77.1%, 65.4%, 66.4%, 94.5%, 96.8%, 80.2%, 82.6%, 
78.2%, 80.2%, 87.2%, & 89.6 % for SE1-SE14 respectively and 
was 39.6 % in 90 min for pure drug. 
In vitro studies reveal that there is marked increase in the 
dissolution rate of Tolvaptan from all the solid dispersions when 
compared to pure Tolvaptan itself. From the in vitro drug release 
profiles, it can be seen that formulation SE8 containing Kleptose  
 
 
 
HPB (1:2:2 1:2:1 ratio of drug: Kleptose HPB:SLS) shown higher 
dissolution rate i.e. 96.8 % compared with other formulations. This 
may be attributed to the increase in drug wettability, conversion to 
amorphous (conformed through DSC /XRD, please present them) 
form and solubilization of the drug due to hydrophilic carrier. The 
increase in dissolution rate is in the order of Kleptose-HPB> HPMC 
AS> Soluplus > Kolliphor P188> Poloxamers (mixture of Kolliphor 
P407 & P188 in 1:1 ratio) > Kolliwax GMS> Kolliphor P407. The 
graphical representation of solid dispersions of SE1-SE4, SE5-
SE8, SE9-SE11 and SE12-SE14 was depicted in Figure 4 and 5 
respectively.  
Table 5: In vitro drug release of pure drug, Innovator product and prepared solid dispersions by solvent evaporation method from SE1 to SE7 
Time in 
min 
Cumulative % drug release* 
Pure drug 
SAMSCA® 
SE1 SE2 SE3 SE4 SE5 SE6 SE7 
0 0 0 0 0 0 0 0 0 0
5 12.2μ2.5 32.4μ2.6 34.5μ1.2 31.9μ0.7 36.7μ1.8 35.6μ1.4 34.4μ1.5 36.5μ1.5 36.3μ1.5
10 18.6μ3.1 49.4μ2.2 54.2μ2.4 49.6μ1.2 46.7μ0.6 44.6μ1.4 43.9μ1.5 45.7μ1.4 46.7μ2.4
20 22.1μ3.6 72.8μ1.6 67.8μ1.5 59.5μ1.5 56.4μ1.8 56.4μ1.5 56.6μ1.2 58.2μ1.2 59.8μ1.5
30 28.9μ3.3 79.2μ1.9 77.5μ1.4 70.0μ1.4 63.7μ1.3 66.5μ1.8 60.8μ1.4 62.4μ2.3 66.3μ1.7
45 32.5μ2.6 89.8μ1.2 86.1μ1.6 78.3μ1.5 70.2μ1.4 73.8μ1.2 62.4μ1.4 63.7μ2.4 74.6μ2.3
60 39.6μ2.7 94.2μ0.9 91.1μ1.5 93.6μ1.3 76.8μ0.6 77.1μ1.1 65.4μ0.4 66.4μ2.1 94.5μ1.5
*MeanμSD, n=3 
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Figure 4: In vitro dissolution profile of pure drug, innovator and Tolvaptan solid dispersions (SE1-SE7) 
Table 6: In vitro drug release of pure drug, Innovator product and prepared solid dispersions by solvent evaporation method from SE8 to SE14 
Time in min 
Cumulative % drug release* 
Pure drug 
SAMSCA® 
SE8 SE9 SE10 SE11 SE12 SE13 SE14 
0 0 0 0 0 0 0 0 0 0
5 12.2μ4.9 32.4μ2.6 36.7μ1.2 45.6μ2.3 35.6μ1.4 34.8μ2.7 46.7μ2.1 46.7μ1.8 31.9μ1.6
10 18.6μ4.1 49.4μ2.2 56.7μ2.4 54.5μ2.2 44.6μ1.4 42.6μ2.4 56.7μ2.4 56.7μ2.3 42.6μ1.5
20 22.1μ3.6 72.8μ1.6 76.4μ2.3 64.4μ2.1 54.6μ1.8 48.7μ2.6 64.6μ2.1 64.6μ2.4 52.5μ1.7
30 28.9μ3.3 79.2μ1.9 83.7μ1.7 68.5μ2.1 62.1μ1.7 52.2μ2.7 67.3μ2.1 67.3μ2.1 60.0μ1.4
45 32.5μ2.6 89.8μ1.2 90.2μ1.4 73.6μ1.4 69.3μ1.6 66.7μ2.4 74.2μ2.2 74.2μ2.3 68.3μ1.5
60 39.6μ2.7 94.2μ0.9 96.8μ1.4 80.2μ1.8 82.6μ1.2 78.2μ2.6 80.2μ2.4 87.2μ2.4 89.6μ1.4
*MeanμSD, n=3 
 
 
Figure 5: In vitro dissolution profile of pure drug, innovator and Tolvaptan solid dispersions (SE8-SE14)
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surfaced, irregular in shape and size. In case of Solid dispersions, 
it was difficult to distinguish the presence of drug crystals. The drug 
surface in solid dispersion seems to be more porous in nature. 
Solid dispersions appeared as uniform and homogeneously mixed 
mass with wrinkled surface. Drug crystals appeared to be 
incorporated into the particles of the polymers. The solid dispersion 
looked like a matrix particle. The results could be attributed to 
dispersion of the drug in the molten mass of the polymer. 
 
 
                 a. Pure drug (Tolvaptan) 
 
                          b. Optimized solid dispersion (SE8) 
Figure 12: SEM pictures of drug and formulation SE8 
Stability studies 
Tolvaptan optimized formulation (SE8) was selected for stability 
studies on the basis of high cumulative % drug release. Stability 
studies were conducted for 6 months according to ICH guidelines. 
To evaluate the physical state of the drug, the samples were 
evaluated for drug content, In vitro drug release profile and 
characterized by XRD after storage for 6 months (Figure 13). The 
samples were found to be stable during a 6-month period. From 
these results it was concluded that, optimized formulation is stable 
and retained their original properties with minor differences which 
depicted in Table 7.  
 
Table 7: Drug content and %drug release of optimized formulation 
stored at 40 μ20C /75 μ5%RH 
Stability period for 
optimized 
formulation 
% Drug content  
In-vitro drug 
release (%)  
Initial 97.90 96.8 
1 Month 96.60 95.70 
2 Months 96.15 95.15 
3 months 95.55 94.50 
6 Months 95.10 93.05 
Pharmacokinetic parameters comparison for pure drug 
suspension and optimized solid dispersions formulation 
The Tolvaptan plasma concentrations in rats treated with optimized 
solid dispersions formulation (SE8) were significantly higher than 
those treated with pure drug suspension. Plasma pharmacokinetic 
parameters of Tolvaptan after oral administration of the formulation 
to Wister rats are shown in Table 8. Based on the results, it was 
clearly evident that Tolvaptan from an optimized solid dispersions 
formulation was significantly increased in comparison with that of 
the pure drug (Tolvaptan suspension). Cmax of the optimized solid 
dispersions formulation was  0.696 øg /ml (p<0.05) and was 
significantly higher as compared to Cmax of the pure drug 
suspension formulation  0.261øg/ml. Tmax of optimized solid 
dispersions formulation and pure drug suspension was 1.00 and 
2.00 h, respectively. AUC is an important parameter in evaluating 
bioavailability of drug from dosage form, as it represents the total 
integrated area under the blood concentration time profile and 
represents the total amount of drug reaching the systemic 
circulation after oral administration. AUC0- inf for optimized solid 
dispersions formulation was higher 6.05 øg h/ml than the pure drug 
suspension  2.85 øg h/ml. Statistically, AUC0-t of the optimized 
solid dispersions formulation was significantly higher (p<0.05) as 
compared to pure drug suspension formulation. Higher amount of 
drug concentration in blood indicated better systemic absorption of 
Tolvaptan from optimized solid dispersions formulation as 
compared to the pure drug suspension.  
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Figure 13: X-Ray powder diffractograms of optimized formulation SE8 (A), optimized formulation SE8 after stability studies (B) 
 
Table 8: Pharmacokinetic Parameters of Tolvaptan from optimized formulation (SE8) and pure drug 
Pharmacokinetic Parameters Tolvaptan Pure drug Tolvaptan free flowing solid 
dispersion (SE8) 
C max (øg/ml) 0.261 0.696 
AUC 0-t (øg h/ml) 2.62 5.52 
AUC 0-inf (øg h/ml) 2.85 6.05 
T max (h) 2.00 1.00 
t 1/2 (h) 3.32 4.52 
K el (h-1) 0.284 0.141 
 
Conclusion 
The dissolution rate of Tolvaptan was increased with solid 
dispersions prepared by solvent evaporation technique using 
Kleptose without any physical and chemical interaction. Solid 
dispersions of drug: Kleptose HPB: SLS (1:2:1 ratio) (SE8) shown 
higher dissolution rate i.e. 96.8 % compared with and pure drug 
(39.6%) and other formulations. Analysis by DSC and powder X-
ray diffraction showed that Tolvaptan existed in the amorphous 
form within the solid dispersion formulation fabricated using the 
solvent evaporation process. Additionally, scanning electron 
microscopy studies suggested the conversion of crystalline 
Tolvaptan to an amorphous form. A marked increase in dissolution 
and bioavailability was exhibited by optimized Tolvaptan solid 
dispersion (SE8).  In vivo studies revealed that AUC (0-t) was 
increased more than 2.11 folds, Cmax increased about 2.67 folds 
and tmax reduced by 1 hr, when compared to the pure drug. Thus, 
the study has illustrated the potential use of a solid dispersion 
system for the delivery of a very poorly soluble drug tolvaptan with 
a better bioavailability. The in vivo studies clearly indicated that 
solid dispersion approach can be adopted for formulation of 
Tolvaptan in order to achieve a faster onset of action. 
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